<p>Krystal Biotech（纳斯达克股票代码：KRYS - 获取免费报告）于周一公布了其财报。该公司报告本季度每股收益为 1.83 美元，超出市场共识预期的 1.45 美元，超出幅度为 0.38 美元，FiscalAI 报道。该季度的营业收入为 1.1636 亿美元，超过分析师预期的 1.1211 亿美元。Krystal Biotech 的股本回报率为 18.69%，净利润率为 52.64%。</p>
<p>获取 <strong>Krystal Biotech</strong> 的提醒：</p>
<h2>Krystal Biotech 股票表现</h2>
<ul>
<li>制药火灾销售：RSI 指标显示的 3 只股票你不应忽视</li>
</ul>
<p>纳斯达克股票代码：KRYS 的股票周一开盘价为 266.04 美元。该公司的 50 日简单移动平均线为 261.72 美元，200 日简单移动平均线为 246.50 美元。Krystal Biotech 的 52 周低点为 122.80 美元，52 周高点为 298.30 美元。该公司的市值为 78.3 亿美元，市盈率为 38.84，贝塔值为 0.50。</p>
<h2>内部交易活动</h2>
<p>在其他新闻中，首席会计官凯瑟琳·罗马诺（Kathryn Romano）于 3 月 2 日（周一）出售了 750 股 Krystal Biotech 的股票，交易平均价格为 267.60 美元，总交易额为 200,700.00 美元。交易后，首席会计官持有该公司 22,366 股股票，估值约为 5,985,141.60 美元。此次交易使其持股比例减少了 3.24%。该交易已在美国证券交易委员会（SEC）备案，相关信息可通过 SEC 网站访问。此外，董事丹尼尔·贾尼（Daniel Janney）于 2 月 27 日（周五）出售了 11,803 股公司的股票，平均售价为 275.59 美元，总价值为 3,252,788.77 美元。交易后，该董事直接持有 73,293 股公司股票，估值为 20,198,817.87 美元。此次交易使其持股比例减少了 13.87%。有关此次出售的更多细节可在 SEC 的官方披露中找到。过去 90 天内，内部人士共出售了 129,164 股公司股票，价值 34,538,578 美元。公司内部人士持有公司股票的 13.10%。</p>
<h2>机构投资者对 Krystal Biotech 的看法</h2>
<ul>
<li>清晰透明：Krystal Biotech 在良好的交易量中突破阻力位</li>
</ul>
<p>一些机构投资者最近买入和卖出了该公司的股票。Greenline Wealth Management LLC 在第四季度购买了 Krystal Biotech 的新头寸，价值约 34,000 美元。Danske Bank A S 在第三季度购买了 Krystal Biotech 的股份，价值约 35,000 美元。UMB Bank n.a.在第四季度增持了 Krystal Biotech 的股份，增幅为 34.6%。UMB Bank n.a.目前持有该公司 144 股股票，价值 36,000 美元，此前在该期间内又购买了 37 股。Global Retirement Partners LLC 在第四季度增持了 Krystal Biotech 的股份，增幅为 788.9%。Global Retirement Partners LLC 目前持有该公司 160 股股票，价值 39,000 美元，此前在该期间内又购买了 142 股。最后，Osaic Holdings Inc.在第二季度增持了 Krystal Biotech 的股份，增幅为 41.4%。Osaic Holdings Inc.目前持有该公司 393 股股票，价值 54,000 美元，此前在上个季度又购买了 115 股。目前 86.29% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师对 KRYS 股票发表了评论。Guggenheim 将 Krystal Biotech 的股票目标价从 224.00 美元上调至 284.00 美元，并在 2 月 25 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 4 月 9 日的研究报告中将 Krystal Biotech 的评级从 “持有（c+）” 上调至 “买入（b-）”。高盛集团在 1 月 30 日的报告中将 Krystal Biotech 的目标价从 206.00 美元上调至 327.00 美元，并给予该股票 “买入” 评级。Wolfe Research 在 3 月 27 日的研究报告中开始覆盖 Krystal Biotech 的股票，并为该公司设定了 “同行表现” 评级。最后，HC Wainwright 在 1 月 9 日的报告中重申了 “买入” 评级，并将 Krystal Biotech 的目标价设定为 310.00 美元（上调自 240.00 美元）。九位投资分析师对该股票给予了 “买入” 评级，另外两位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 326.25 美元。</p>
<p><strong>查看我们对 KRYS 的最新股票分析</strong></p>
<h2>Krystal Biotech 公司简介</h2>
<p>（获取免费报告）</p>
<p>Krystal Biotech, Inc 是一家临床阶段的生物技术公司，专注于开发针对罕见皮肤病的基因疗法。公司总部位于宾夕法尼亚州匹兹堡，应用专有的病毒载体递送技术，使纠正基因能够直接通过皮肤进行局部给药。通过针对遗传性皮肤病的根本遗传原因，Krystal Biotech 旨在解决高未满足医疗需求的领域，提供潜在的变革性治疗。</p>
<p>该公司的主要产品候选药物 KB103 旨在向患有营养不良性表皮松解症（DEB）患者传递功能性 COL7A1 基因，这是一种严重且常常使人虚弱的水疱性疾病。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 Krystal Biotech</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUtSWVM?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUtSWVM"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Krystal Biotech 吗？</h2>
<p>在你考虑 Krystal Biotech 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Krystal Biotech 并不在名单上。</p>
<p>虽然 Krystal Biotech 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KRYS

IBBQ

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Krystal Biotech（纳斯达克代码：KRYS）报告的季度每股收益为 1.83 美元，超出预期 0.38 美元。该公司实现收入 1.1636 亿美元，超过市场共识预期的 1.1211 亿美元。Krystal Biotech 的净利润率为 52.64%，股本回报率为 18.69%，股票表现依然强劲，市值为 78.3 亿美元。近期内部人士的出售和机构投资表明交易活跃，而分析师们则保持乐观展望，给予多项买入评级，目标价共识为 326.25 美元</p>

<p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its earnings results on Monday. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38, FiscalAI reports. The business had revenue of $116.36 million during the quarter, compared to analysts' expectations of $112.11 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.</p>
<div class="lb-trans"><p>Krystal Biotech（纳斯达克股票代码：KRYS - 获取免费报告）于周一公布了其财报。该公司报告本季度每股收益为 1.83 美元，超出市场共识预期的 1.45 美元，超出幅度为 0.38 美元，FiscalAI 报道。该季度的营业收入为 1.1636 亿美元，超过分析师预期的 1.1211 亿美元。Krystal Biotech 的股本回报率为 18.69%，净利润率为 52.64%。</p>
</div><p>Get <strong>Krystal Biotech</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Krystal Biotech</strong> 的提醒：</p>
</div><h2>Krystal Biotech Stock Performance</h2>
<div class="lb-trans"><h2>Krystal Biotech 股票表现</h2>
</div><ul>
<li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>制药火灾销售：RSI 指标显示的 3 只股票你不应忽视</li>
</ul>
</div><p>Shares of NASDAQ:KRYS opened at $266.04 on Monday. The firm has a 50 day simple moving average of $261.72 and a 200 day simple moving average of $246.50. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30. The company has a market cap of $7.83 billion, a PE ratio of 38.84 and a beta of 0.50.</p>
<div class="lb-trans"><p>纳斯达克股票代码：KRYS 的股票周一开盘价为 266.04 美元。该公司的 50 日简单移动平均线为 261.72 美元，200 日简单移动平均线为 246.50 美元。Krystal Biotech 的 52 周低点为 122.80 美元，52 周高点为 298.30 美元。该公司的市值为 78.3 亿美元，市盈率为 38.84，贝塔值为 0.50。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In other news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the transaction, the chief accounting officer owned 22,366 shares in the company, valued at approximately $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Daniel Janney sold 11,803 shares of the company's stock in a transaction on Friday, February 27th. The shares were sold at an average price of $275.59, for a total value of $3,252,788.77. Following the transaction, the director directly owned 73,293 shares in the company, valued at $20,198,817.87. The trade was a 13.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 129,164 shares of company stock valued at $34,538,578 in the last 90 days. Company insiders own 13.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席会计官凯瑟琳·罗马诺（Kathryn Romano）于 3 月 2 日（周一）出售了 750 股 Krystal Biotech 的股票，交易平均价格为 267.60 美元，总交易额为 200,700.00 美元。交易后，首席会计官持有该公司 22,366 股股票，估值约为 5,985,141.60 美元。此次交易使其持股比例减少了 3.24%。该交易已在美国证券交易委员会（SEC）备案，相关信息可通过 SEC 网站访问。此外，董事丹尼尔·贾尼（Daniel Janney）于 2 月 27 日（周五）出售了 11,803 股公司的股票，平均售价为 275.59 美元，总价值为 3,252,788.77 美元。交易后，该董事直接持有 73,293 股公司股票，估值为 20,198,817.87 美元。此次交易使其持股比例减少了 13.87%。有关此次出售的更多细节可在 SEC 的官方披露中找到。过去 90 天内，内部人士共出售了 129,164 股公司股票，价值 34,538,578 美元。公司内部人士持有公司股票的 13.10%。</p>
</div><h2>Institutional Investors Weigh In On Krystal Biotech</h2>
<div class="lb-trans"><h2>机构投资者对 Krystal Biotech 的看法</h2>
</div><ul>
<li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li>
</ul>
<div class="lb-trans"><ul>
<li>清晰透明：Krystal Biotech 在良好的交易量中突破阻力位</li>
</ul>
</div><p>A number of institutional investors have recently bought and sold shares of the business. Greenline Wealth Management LLC purchased a new position in Krystal Biotech during the 4th quarter valued at about $34,000. Danske Bank A S purchased a new stake in shares of Krystal Biotech in the third quarter worth approximately $35,000. UMB Bank n.a. boosted its holdings in shares of Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company's stock worth $36,000 after purchasing an additional 37 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company's stock worth $39,000 after purchasing an additional 142 shares during the period. Finally, Osaic Holdings Inc. grew its position in Krystal Biotech by 41.4% during the second quarter. Osaic Holdings Inc. now owns 393 shares of the company's stock valued at $54,000 after purchasing an additional 115 shares in the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者最近买入和卖出了该公司的股票。Greenline Wealth Management LLC 在第四季度购买了 Krystal Biotech 的新头寸，价值约 34,000 美元。Danske Bank A S 在第三季度购买了 Krystal Biotech 的股份，价值约 35,000 美元。UMB Bank n.a.在第四季度增持了 Krystal Biotech 的股份，增幅为 34.6%。UMB Bank n.a.目前持有该公司 144 股股票，价值 36,000 美元，此前在该期间内又购买了 37 股。Global Retirement Partners LLC 在第四季度增持了 Krystal Biotech 的股份，增幅为 788.9%。Global Retirement Partners LLC 目前持有该公司 160 股股票，价值 39,000 美元，此前在该期间内又购买了 142 股。最后，Osaic Holdings Inc.在第二季度增持了 Krystal Biotech 的股份，增幅为 41.4%。Osaic Holdings Inc.目前持有该公司 393 股股票，价值 54,000 美元，此前在上个季度又购买了 115 股。目前 86.29% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have commented on KRYS shares. Guggenheim boosted their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a &#34;buy&#34; rating in a research report on Wednesday, February 25th. Weiss Ratings raised shares of Krystal Biotech from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research note on Thursday, April 9th. The Goldman Sachs Group boosted their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, January 30th. Wolfe Research began coverage on shares of Krystal Biotech in a research note on Friday, March 27th. They set a &#34;peer perform&#34; rating for the company. Finally, HC Wainwright restated a &#34;buy&#34; rating and set a $310.00 target price (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $326.25.</p>
<div class="lb-trans"><p>几位股票研究分析师对 KRYS 股票发表了评论。Guggenheim 将 Krystal Biotech 的股票目标价从 224.00 美元上调至 284.00 美元，并在 2 月 25 日的研究报告中给予该股票 “买入” 评级。Weiss Ratings 在 4 月 9 日的研究报告中将 Krystal Biotech 的评级从 “持有（c+）” 上调至 “买入（b-）”。高盛集团在 1 月 30 日的报告中将 Krystal Biotech 的目标价从 206.00 美元上调至 327.00 美元，并给予该股票 “买入” 评级。Wolfe Research 在 3 月 27 日的研究报告中开始覆盖 Krystal Biotech 的股票，并为该公司设定了 “同行表现” 评级。最后，HC Wainwright 在 1 月 9 日的报告中重申了 “买入” 评级，并将 Krystal Biotech 的目标价设定为 310.00 美元（上调自 240.00 美元）。九位投资分析师对该股票给予了 “买入” 评级，另外两位分析师给予了 “持有” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 326.25 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on KRYS</strong></p>
<div class="lb-trans"><p><strong>查看我们对 KRYS 的最新股票分析</strong></p>
</div><h2>Krystal Biotech Company Profile</h2>
<div class="lb-trans"><h2>Krystal Biotech 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.</p>
<div class="lb-trans"><p>Krystal Biotech, Inc 是一家临床阶段的生物技术公司，专注于开发针对罕见皮肤病的基因疗法。公司总部位于宾夕法尼亚州匹兹堡，应用专有的病毒载体递送技术，使纠正基因能够直接通过皮肤进行局部给药。通过针对遗传性皮肤病的根本遗传原因，Krystal Biotech 旨在解决高未满足医疗需求的领域，提供潜在的变革性治疗。</p>
</div><p>The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.</p>
<div class="lb-trans"><p>该公司的主要产品候选药物 KB103 旨在向患有营养不良性表皮松解症（DEB）患者传递功能性 COL7A1 基因，这是一种严重且常常使人虚弱的水疱性疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Krystal Biotech</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Krystal Biotech</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9S1JZUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=KRYS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Krystal Biotech 吗？</h2>
</div><p>Before you consider Krystal Biotech, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Krystal Biotech 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Krystal Biotech 并不在名单上。</p>
</div><p>While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Krystal Biotech 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Krystal Biotech (NASDAQ:KRYS) Releases Quarterly Earnings Results, Beats Expectations By $0.38 EPS

Market Beat

Krystal Biotech

Invesco Nasdaq Biotechnology ETF

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

丹麦银行(ADR)

UMB金融

高盛

GS Hldg R

Krystal Biotech (NASDAQ:KRYS) 公布季度财报，每股收益超出预期 $0.38